POLICY NUMBER  
UM ONC_1039

SUBJECT  
Faslodex™ (fulvestrant)

DEPT/PROGRAM  
UM Dept

PAGE 1 OF 2

POLICY NUMBER  
UM ONC_1039

SUBJECT  
Faslodex™ (fulvestrant)

DEPT/PROGRAM  
UM Dept

DATE REVIEWED  
01/12/11, 03/08/12, 10/30/13, 03/05/15, 04/11/16, 02/06/17, 01/10/18, 02/13/19, 12/11/19, 02/12/20, 04/08/20

APPROVAL DATE  
April 8, 2020

EFFECTIVE DATE  
April 24, 2020

REVISION DATES (latest version listed last)  
01/12/11, 03/08/12, 10/30/13, 03/05/15, 04/11/16, 02/06/17, 01/10/18, 02/13/19, 12/11/19, 02/12/20, 04/08/20

PRIME BUSINESS OWNER: UM  
APPROVED BY: Dr. Andrew Hertler

COMMITTEE/BOARD APPROVAL  
Utilization Management Committee

URAC STANDARDS  
HUM 1

NCQA STANDARDS  
UM 2

ADDITIONAL AREAS OF IMPACT  
CMS REQUIREMENTS

STATE/FEDERAL REQUIREMENTS

APPLICABLE LINES OF BUSINESS  
Commercial, Exchange, Medicaid

I. PURPOSE

To define and describe the accepted indications for Faslodex (fulvestrant) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century is responsible for processing all medication requests from network ordering providers. Medications not authorized by New Century may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

II. INDICATIONS FOR USE/INCLUSION CRITERIA

1. PREFERRED MEDICATION GUIDANCE FOR INITIAL REQUEST:

a. When health plan Medicaid coverage provisions- including any applicable PDLs (Preferred Drug Lists)- conflict with the coverage provisions in this drug policy, health plan Medicaid coverage provisions take precedence per the Preferred Drug Guidelines OR

b. When health plan Exchange coverage provisions- including any applicable PDLs (Preferred Drug Lists)- conflict with the coverage provisions in this drug policy, health plan Exchange coverage provisions take precedence per the Preferred Drug Guidelines OR

c. For Health Plans that utilize NCH UM Oncology Clinical Policies as the initial clinical criteria, the Preferred Drug Guidelines shall follow NCH L1 Pathways when applicable, otherwise shall follow NCH drug policies: http://pathways.newcenturyhealth.com AND

d. Continuation requests of previously approved non-preferred medication are not subject to this provision AND

e. When available, generic alternatives are preferred over brand-name drugs.

2. Metastatic Breast Cancer ER/PR positive

a. NOTES: NCH Pathway L1 Preferred Regimens for ER/PR positive metastatic breast cancer, for first line/initial therapy are Ribociclib/Palbociclib + Aromatase Inhibitor. Abemaciclib/Palbociclib +/- Fulvestrant is preferred in the subsequent or second line setting.
b. The member is post-menopausal or if the member is pre-menopausal, she is receiving concomitant ovarian ablation/suppression.

c. Faslodex may be used as ANY of the following:
   a. In combination with a CDK4/6 inhibitor e.g. palbociclib, abemaciclib, ribociclib,
   a. In combination with alpelisib, if PIK3CA mutation positive, as second line therapy
   b. In combination with trastuzumab for HER2-positive disease.

III. EXCLUSION CRITERIA
   1. The member is a premenopausal female who is not receiving concomitant ovarian ablation/suppression.
   2. The member has hormone receptor negative tumor.
   3. Dosing exceeds single dose limit of 500 mg.
   4. Indications not supported by CMS recognized compendia or acceptable peer reviewed literature.

IV. MEDICATION MANAGEMENT
   Please refer to the FDA label/package insert for details regarding these topics.

V. APPROVAL AUTHORITY
   1. Review – Utilization Management Department
   2. Final Approval – Utilization Management Committee

VI. ATTACHMENTS
   None

VII. REFERENCES